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The C-Jun N-terminal Kinase (JNK) inhibitor SP600125 is widely used to inhibit the JNK-mediated
Bax activation and cell apoptosis. However, this report demonstrates that SP600125 synergistically
enhances the dihydroartemisinin (DHA)-induced human lung adenocarcinoma cell apoptosis by
accelerating Bax translocation and subsequent intrinsic apoptotic pathway involving mitochondrial
membrane depolarization, cytochrome c release, caspase-9 and caspase-3 activation. The dynamical
analysis of GFP-Bax mobility inside single living cells using ﬂuorescence recovery after photobleach-
ing revealed that SP600125 aggravated the DHA-induced decrease of Bax mobility and Bax translo-
cation. These results for the ﬁrst time present a novel pro-apoptotic action of SP600125 in
DHA-induced apoptosis.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Dihydroartemisinin (DHA), a semi-synthetic derivative of arte-
misinin, isolated from the traditional Chinese herb Artemisia annua,
is recommended as a safe and effective mainstay in treating malar-
ia by WHO [1]. Many recent studies have revealed that DHA can
inhibit the growth of cancer cells through the apoptotic pathway
[2–8]. Speciﬁcally, DHA-induced tumor cell apoptosis is implicated
in the causation of G0/G1 cell cycle arrest [4], activation of caspases
[3–6] and p38 kinase [7], decrease of Bcl-2/Bax expression ratio
[4,6] and regulation of angiogenesis-related genes [8].
C-Jun N-terminal Kinase (JNK), a member of the mitogen-acti-
vated protein kinase (MAPK) family, has been implicated in the re-
sponse of tumor cells to chemotherapeutic drugs [9]. It has been
well established that JNK plays a critical role in death receptor-
initiated extrinsic as well as mitochondrial intrinsic apoptotic
pathway [9,10]. Most commonly, JNK is thought to induce mito-chemical Societies. Published by E
taurosporine; ROS, reactive
cell counting kit; FCM, Flow
aching; DWm, mitochondrial
t.c, GFP-cytochrome cchondria-dependent apoptosis mainly through directly or indi-
rectly activating Bax [11–15], a pro-apoptotic Bcl-2 family
member, which plays an essential role in inducing apoptosis [16].
SP600125 is an anthrapyrazole, a small molecule that acts as a
reversible, ATP-competitive inhibitor of JNK1/2 [17]. Because of
the speciﬁcity and effectiveness in both cultured cells and whole
animals, SP600125 has become the choice of pharmacological
inhibitor for assessing the role of JNK in mediating biological
processes.
To explore whether JNK mediates DHA-induced Bax transloca-
tion into mitochondria and cell apoptosis, this report assesses the
action of the recently described JNK inhibitor SP600125 during
DHA-induced human lung adenocarcinoma (ASTC-a-1) cell apopto-
sis. Our data for the ﬁrst time demonstrates that DHA does not
activate JNK, and SP600125 enhances the DHA-induced Bax activa-
tion and cell apoptosis.2. Materials and methods
2.1. Cell culture, transfection and treatment
Human lung adenocarcinoma ASTC-a-1 and A549 cell lines
were obtained from the Department of Medicine, Jinan Universitylsevier B.V. All rights reserved.
4020 Y.-Y. Lu et al. / FEBS Letters 584 (2010) 4019–4026(Guangzhou, China), and cultured in DMEM (GIBCO) supplemented
with 10% fetal calf serum (Sijiqing, Hangzhou, China) in 5% CO2 at
37 C in a humidiﬁed incubator. For ﬂuorescence experiments, cells
were transiently transfected with plasmids using lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA) in 35-mm dish for 24–48 h.
For every experiment described here, a lethal concentration of
20 lg/ml DHA (Bide Pharmaceutical Corporation, Guangzhou, Chi-
na) based on our previous study [3] was used. Cells were pre-
treated with SP600125 (Sigma, St.Louis, MO, USA) for 1 h, and
then incubated with DHA for indicated times.
2.2. Cell viability and apoptosis assay
Cell viability was assessed by cell counting kit (CCK-8; Dojindo
Laboratories, Kumamoto, Japan) assay as previously described [3].
All experiments were performed in quadruple on three separate
occasions. Cell apoptosis detection was performed by ﬂow cytom-
etry (FCM) analysis using Annexin V-FITC/PI apoptosis detection
kit (Bender Medsystems, Vienna, Austria) as previously described
[3], and for each FCM analysis 10,000 events were recorded.
2.3. Measurement of intracellular reactive oxygen species (ROS)
generation
ROS generation inside living cells was measured by FCM analy-
sis using DCFH-DA (Wako Ltd, Osaka, Japan), an oxidation-sensitive
probe, which was cleaved intracellularly by non-speciﬁc esterases
and turns to highly ﬂuorescent DCF upon oxidation by ROS. For
each analysis 10,000 events were recorded.
2.4. Fluorescence recovery after photobleaching (FRAP) analysis inside
single living cell
To investigate the mobility of GFP-Bax after different treat-
ments, the GFP in the indicating regions of living cells were photo-
bleached by scanning the region with the maximal 488 nm laser
line, and subsequent the entire cell was imaged at every 5 s with
a low laser power (5% power) excitation for a duration of 500 s
to monitor the recovery of ﬂuorescence.
2.5. Detection of Bax translocation and cytochrome c release
A confocal laser scanning microscope (LSM510/ConfoCor2,
Zeiss, Jena, Germany) was used to perform ﬂuorescence imaging
of Bax translocation and cytochrome c release inside single living
cells. Images of cells co-expressing GFP-Bax or GFP-cytochrome c
(GFP-Cyt.c) and DsRed-Mito were collected using dual ﬂuorescence
channels. The excitation wavelengths were 488 nm for GFP and
543 nm for DsRed. The emission ﬂuorescence channels were
500–550 nm for GFP and 600–650 nm for DsRed.
2.6. Measurement of mitochondrial membrane potential (DWm)
Rhodamine123 (Rho123; Sigma), a potential-sensitive dye, was
used to evaluate changes in DWm by FCM as previously described
[3]. Results were expressed as the proportion of cells with lost or
low DWm which was estimated by reduced ﬂuorescence intensity
from Rho123, and for each analysis 10,000 events were recorded.
2.7. Fluorometric assay for caspase activity
Activities of caspase-9 and -3 were measured using ﬂuorogenic
substrates Ac-LEHD-AFC and Ac-DEVD-AFC (Alexis Biochemicals,
Lausen, Switzerland) as previously described [3]. Caspase activity
was measured continuously by monitoring the release of ﬂuorigen-
ic AFC using auto microplate reader (inﬁnite M200, Tecan, Austria).Caspase-like activity was reported as the ratio of the ﬂuorescence
output in treated samples relative to untreated controls.
2.8. Western blot analysis
Preparation of whole cell lysates and Western blot were carried
out as previously described [3]. Anti-phospho-JNK, anti-JNK, anti-
b-actin, anti-Bax, and anti-Cox IV antibodies were obtained from
Cell Signaling (Beverly, MA, USA). Anti-cytochrome c antibody
was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). IR-
Dye Rdye 800CW anti-rabbit IgG and Alexa Fluor 680 goat
anti-Mouse IgG were purchased from Molecular Probes (Eugene,
OR, USA). Detection was performed using the Odyssey Scanning
Infrared Fluorescence Imaging System (LI-COR, USA).
2.9. Statistics analysis
Results were expressed as mean ± standard deviation (S.D.). Dif-
ferences between groups were compared using Student’s t-test by
SPSS software. Signiﬁcance was deﬁned as P < 0.05.3. Results
3.1. SP600125 pretreatment enhanced DHA-induced cell apoptosis
We found that SP600125 treatment alone did not affect cell
growth, whereas pretreating ASTC-a-1 cells with 10 or 20 lM
SP600125 signiﬁcantly increased DHA-induced cell cytotoxicity
(Fig. 1A). Meanwhile, cells were treated with DHA for 0, 12 and
24 h in the absence or presence of 0.5 and 1 ll DMSO which were
equivalent to that in 10 and 20 lM SP600125, respectively. In or-
der to avoid the vehicle (DMSO) response, 10 lM of SP600125 was
selected for every experiment without indicated concentration in
this report. Also, the augment of SP600125 on DHA-induced cell
death was observed in A549 cell line (Fig. 1B). However,
SP600125 did not have a similar effect on Staurosporine (STS;
Alexis Biochemicals, Lausen, Switzerland) -induced cell death
(Fig. 1C), suggesting a speciﬁc role of SP600125 in conjunction
with DHA.
To determine whether SP600125 enhanced the DHA-induced
cell death through accelerating apoptosis, the early apoptotic
characteristic of phosphatidyl serine (PS) externalization was
quantiﬁed by annexin V/PI staining. As shown in Fig. 1D, the per-
centage of apoptosis in ASTC-a-1 cells cotreated with DHA and
SP600125 (45.6%) was signiﬁcantly higher than that in cells ex-
posed to DHA (29.3%) or SP600125 (3.3%) alone, indicating a poten-
tial synergistic effect of SP600125 on cell apoptosis. ASTC-a-1 cell
line was selected for every experiment without indication in this
report.
3.2. DHA did not activate JNK pathway
Firstly, anisomycin (Alexis Biochemicals, Lausen, Switzerland), a
well-known JNK activator, was used to investigate whether JNK
could be activated and SP600125 acted as a JNK inhibitor. As
shown in Fig. 2A and B, our results showed that treating cells with
1 or 1.5 lg/ml anisomycin for 2 h signiﬁcantly induced the phos-
phorylation of JNK, whereas SP600125 pretreatment markedly
blocked JNK phosphorylation, in which DHA did not inﬂuence the
inhibitory effect of SP600125 on JNK phosphorylation.
Next, to assess whether JNK was involved in the DHA-induced
apoptosis, we detected the JNK phosphorylation at 0, 6, 12 and
24 h after DHA treatment. As shown in Fig. 2C, in contrast to aniso-
mycin treatment, although DHA treatment did not activate JNK, we
noticed that treating cells with DHA for 12 or 24 h not 6 h induced
Fig. 1. SP600125 pretreatment enhanced DHA-induced ASTC-a-1 cell apoptosis. (A) Effect of SP600125 pretreatment on DHA-induced cytotoxicity by CCK-8. Cells were
treated with 20 lg/ml DHA for 0, 12 and 24 h in the presence or absence of DMSO and 1, 5, 10 or 20 lM SP600125, respectively. **P < 0.01, compared with control; #P < 0.05,
##P < 0.01, compared with DHA treatment alone. (B) Effect of SP600125 pretreatment on DHA-induced cytotoxicity by CCK-8 in A549 cells. Cells were treated with 20 lg/ml
of DHA for 0, 12 and 24 h in the presence or absence of 10 lV SP600125. **P < 0.01, compared with control; ##P < 0.01, compared with DHA treatment alone. (C) Effect of
SP600125 pretreatment on STS-induced cytotoxicity by CCK-8. Cells were treated with 1 lM STS for 0 and 6 h in the presence or absence of 10 lM SP600125, respectively.
**P < 0.01, compared with control. (D) FCM analysis of apoptosis of cells upon different treatments. Cells were treated with DHA for 0 and 24 h with or without the addition of
SP600125 and then stained with Annexin V-FITC/PI before being analyzed by FCM. STS-treated cells were used as a positive control.
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treatment of Z-VAD-fmk, a broad spectrum caspase inhibitor.
These results implied that the signiﬁcant decrease of JNK protein
level in response to DHA treatment was possibly due to cell
death.
3.3. SP600125 pretreatment attenuated DHA-elicited ROS generation
We found that N-acetyl cysteine (NAC; Sigma), a ROS scavenger,
signiﬁcantly inhibited the DHA-induced cytotoxicity (Fig. S1),demonstrating that DHA-elicited ROS, mostly due to the reaction
of endoperoxide bridge of DHA with heme irons [18], mediated
the DHA-induced apoptosis. To determine the effect of SP600125
on DHA-elicited ROS, we used DCFH-DA to detect the ROS level in-
side living cells. Results from FCM analysis (Fig. 2D) consistently
demonstrated that DHA treatment induced a rapid increase in
DCF ﬂuorescence, which was remarkably attenuated by
SP600125 pretreatment, indicating that the synergistic effect of
SP600125 on DHA-induced apoptosis was not owing to promoting
the DHA-elicited ROS generation.
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by DHA
Here, we used FRAP technique to assess Bax mobility inside sin-
gle living cells showing even distribution of GFP-Bax in cytoplasm
during DHA-induced apoptosis. We noticed a rapid reﬁlling of GFP-
Bax in the photobleached area for control cell (Fig. 3A: control) as
well as the cells treated with SP600125 alone (Fig. 3A: SP600125),
conﬁrming that GFP-Bax is a soluble protein with high mobility in
untreated cells. However, DHA treatment induced a slow reﬁlling
of GFP-Bax in the photobleached area (Fig. 3A: DHA), which might
be due to both the Bax conformational change and partially
binding to certain organelles. Strikingly, co-treating cells with
SP600125 and DHA almost blocked the ﬂuorescence recovery in
the photobleached area (Fig. 3A: DHA + SP600125). Fig. 3B showed
the dynamics of FRAP from 50 to 60 cells in three independentFig. 2. DHA did not activate JNK pathway and SP600125 pretreatment attenuated DHA
indicated treatments were analyzed by Western blot with anti-phospho-JNK, anti-JNK, b-
(D) FCM analysis of ROS generation. Untreated or treated cells were harvested and stainexperiments for control, SP600125-treated, DHA-treated, DHA-
and SP600125-cotreated cells. These results suggested that
SP600125 pretreatment signiﬁcantly aggravated the DHA-induced
decrease of Bax mobility, which might be due to the conforma-
tional change and oligomerization of Bax before the formation of
Bax clusters.
3.5. SP600125 pretreatment promoted DHA-induced Bax translocation
into mitochondria
In contrast to control cells (Fig. 3A: control), co-treating cells
with SP600125 and DHA induced Bax clusters formation, in which
the ﬂuorescence recovery in the photobleached area was com-
pletely blocked (Fig. 3C), which was consistent with the dynamics
of FRAP from 50 to 60 cells in three independent experiments
shown in Fig. 3D. These results demonstrated that Bax irreversibly-elicited ROS generation. (A–C) Soluble protein extracts obtained from cells under
actin antibodies, respectively. Anisomycin treatment was used as a positive control.
ed with 20 lM DCFH-DA for 30 min in the dark before being analyzed by FCM.
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endoplasmic reticulum during apoptosis induced by SP600125 and
DHA cotreatment.
Next, we used confocal ﬂuorescence microscopy to image the
spatial distribution of Bax and mitochondria inside single livingFig. 3. SP600125 pretreatment aggravated the decrease of Bax mobility by DHA and prom
imaging of the mobility of GFP-Bax during photobleaching under different treatments.
experiments for each condition. (C) Typical time-lapse imaging of the mobility of GFP-Bax
Scale Bar: 5 lm. (D) Dynamics of FRAP inside living cells from 50 to 60 cells in three indep
images of the spatial distribution of Bax and mitochondria inside single living cells co
showing GFP-Bax translocation. Cells were treated with DHA for 0 and 24 h in the presen
experiments. **P < 0.01, compared with control; ##P < 0.01, compared with DHA treatmecells co-expressing GFP-Bax and DsRed-Mito. We found that co-
treatment with DHA and SP600125 induced Bax translocation into
mitochondria as revealed by the overlaps of GFP-Bax and DsRed-
Mito (Fig. 3E). Statistical results from 300 cells in three
independent experiments (Fig. 3F) showed that at 24 h after DHAoted the DHA-induced Bax translocation into mitochondria. (A) Typical time-lapse
Scale Bar: 5 lm. (B) Dynamics of FRAP from 50 to 60 cells in three independent
during photobleaching in cells showing Bax clusters under SP600125 pretreatment.
endent experiments for DHA and SP600125-cotreated cells. (E) Typical ﬂuorescence
-expressing GFP-Bax and DsRed-Mito. Scale Bar: 20 lm. (F) Quantiﬁcation of cells
ce or absence of SP600125. Data were obtained from 300 cells in three independent
nt alone.
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mitochondria increased from 4.85 ± 1.5% (control cells) to
29 ± 2.1%, which was raised to 43.25 ± 4.05% in the presence of
SP600125, suggesting that SP600125 enhanced the DHA-induced
apoptosis by promoting the DHA-induced Bax translocation into
mitochondria.
3.6. SP600125 pretreatment promoted DHA-induced mitochondrial
apoptotic pathway
Firstly, we used FCM to evaluate the mitochondrial membrane
depolarization indicating the loss of DWm by measuring the ﬂuo-
rescence of Rho123 under various treatments. At 12 and 24 h after
DHA treatment, the percentage of cells with lost or low Rho123Fig. 4. SP600125 pretreatment promoted the DHA-induced mitochondrial membrane dep
(A) FCM analysis of the loss of DWm upon different treatments. Cells were treated with D
Rho123 before being analyzed by FCM. (B) Typical ﬂuorescence images of cytochrome c re
cells showing cytochrome c release. Data were obtained from 300 cells in three independ
treatment alone. (D) Western blot analysis of Bax translocation and cytochrome c release
cytosolic and mitochondrial proteins were extracted using a mitochondria/cytosol fractio
IV and b-actin. (E, F) Detection of caspase-9 and caspase-3 activation by ﬂuorometric ass
treated cells were used as a positive control. Caspase activity was measured using th
determined as the ratio between the activity in extracts of treated cells to that measur
independent experiments. **P < 0.01, compared with control; #P < 0.05, ##P < 0.01, compﬂuorescence intensity were 14.2% and 30.3%, which increased to
20.7% and 45.1% in the case of SP600125 pretreatment, respec-
tively (Fig. 4A), indicating that SP600125 pretreatment promoted
the DHA-induced mitochondrial membrane depolarization.
Secondly, the release of cytochrome cwas investigated in single
living cells co-expressing GFP-Cyt.c and DsRed-Mito using time-
lapse confocal ﬂuorescence microscopy. As shown in Fig. 4B,
GFP-Cyt.c completely localized on mitochondria (DsRed-Mito) in
control cell (upper panel), while DHA induced cytochrome c release
(middle panel), and SP600125 aggravated the DHA-induced cyto-
crome c release (lower panel). Statistical results from 300 cells in
three independent experiments (Fig. 4C) showed that at 24 h after
DHA treatment, the percentage of cells showing cytochrome c re-
lease was increased from 6.1 ± 2.02% (control) to 31.8 ± 6.13%,olarization, cytochrome c release, subsequently caspase-9 and caspase-3 activation.
HA for 0, 12 and 24 h in the presence or absence of SP600125 and then stained with
lease in living cells under different treatments. Scale Bar: 5 lm. (C) Quantiﬁcation of
ent experiments. **P < 0.01, compared with control; #P < 0.05, compared with DHA
. Cells were treated with DHA for 24 h in the presence or absence of SP600125. The
nation kit and then analyzed byWestern blot using antibodies against Bax, Cyt.c, Cox
ay. Cells were treated with DHA for 0 and 24 h with or without SP600125, and STS-
e ﬂuorescence substrate as described in Section 2, and the activation index was
ed in extracts of control cells. Data were analyzed with SPSS10.0 software in three
ared with DHA treatment alone.
Fig. 4 (continued)
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western blot analysis further conﬁrmed that SP600125 pretreat-
ment enhanced the DHA-induced cytochrome c release as well as
the translocation of Bax into mitochondria (Fig. 4D).
Thirdly, the activation of caspase-9 was evaluated by determin-
ing ﬂuorogenic AFC release. Ac-LEHD-AFC, which can be cleaved by
caspase-9-like proteases, was associated with caspase-9 activation.
STS-treated cells were used as a positive control. As can be seen in
Fig. 4E, DHA induced a nearly 1.6-fold increase of caspase-9 activ-
ity compared with control, while co-treatment with SP600125 and
DHA modestly enhanced the caspase-9 activity compared with
DHA treatment alone, indicating that SP600125 pretreatment en-
hanced the DHA-induced caspase-9 activation. Likewise, the acti-
vation of caspase-3 was also evaluated by determining
ﬂuorogenic AFC release. As can be seen in Fig. 4F, DHA induced a
nearly 1.7-fold increase of caspase-3 activity compared with con-
trol, while co-treatment with SP600125 and DHA signiﬁcantly en-
hanced the caspase-3 activity compared with DHA treatment
alone, suggesting that SP600125 pretreatment enhanced the
DHA-induced caspase-3 activation.
Collectively, these results revealed that SP600125 pretreatment
promoted the DHA-induced mitochondrial membrane depolariza-
tion, cytochrome c release, and subsequent caspase-9 and cas-
pase-3 activation.
4. Discussion
SP600125 is widely and commonly used for assessing the com-
plex roles of JNK in mediating biological processes [17]. However,
in our experimental system, SP600125 is not functioning as a sim-
ple JNK inhibitor, which supports a novel pro-apoptotic role for
SP600125 in conjunction with DHA and encourages us to verify
its underlying mechanism.
ROS, recommended as important mediators for apoptotic sig-
naling pathway, are thought to be associated with a number of hu-
man diseases, especially cancer [19]. A burst of exogenous ROS
generation has been observed in DHA-induced apoptosis [5], which
is mostly due to the reaction of endoperoxide bridge of DHA withheme irons [18]. The present study showed that SP600125 pre-
treatment did not promote, but markedly attenuated the DHA-in-
duced ROS burst (Fig. 2D). Accordingly, it is possible that ROS
over-scavenging lead to cell apoptosis.
Mostly, JNK mediates Bax activation and translocation, and
these events can be signiﬁcantly blocked by SP600125 [11]. How-
ever, in our system, SP600125 pretreatment enhances the DHA-in-
duced Bax activation and translocation into mitochondria (Fig. 3),
which may be responsible largely for the synergistic effect of this
combination treatment. It has been reported that Mcl-1, an anti-
apoptotic member of the Bcl-2 family, inhibits Bax activation and
translocation into mitochondria independent of an interaction be-
tween these two proteins [20]. Therefore, we assessed the effect
of Mcl-1 on the augment of SP600125 in the DHA-induced apopto-
sis (Fig. S2). Our results showed that silencingMcl-1 by transfection
of shMcl-1-980 or shMcl-1-1039 both markably decreased the cell
viability either in DHA-treated or DHA and SP600125-cotreated
cells compared with the cells without shMcl-1 transfection. How-
ever, transfection of shMcl-1 caused no signiﬁcant difference in cell
viability between DHA-treated and DHA and SP600125-cotreated
cells, implying that the function of Mcl-1 was not responsible for
the synergistic effect of SP600125 on DHA-induced apoptosis. Addi-
tionally, we found that the overexpression of Bcl-xL, an another
anti-apoptotic members of Bcl-2 family, prevented DHA-induced
Bax translocation (data not shown). Therefore, our further studies
would focus on the conﬁrmation of the action of Bcl-xL, Mcl-1 or
other mediators in DHA/SP600125-induced apoptosis.
Our present ﬁndings demonstrate that SP600125 pretreatment
enhances DHA-induced apoptosis mainly through a mitochondrial
apoptotic pathway involving mitochondrial membrane depolariza-
tion, cytochrome c release, and subsequent caspase-9 and caspase-
3 activation. Moreover, one point worthy to be mentioned was that
SP600125 pretreatment remarkably promoted caspase-3 activa-
tion (Fig. 4F), but modestly enhanced the cytochrome c release
and caspase-9 activation (Fig. 4B–E). It is therefore possible that
SP600125 pretreatment induce the release of other mitochondrial
apoptotic factors, such as Smac/DIABLO, which activate caspase-3
by blocking the inhibitors of apoptosis (IAPs) [21].
4026 Y.-Y. Lu et al. / FEBS Letters 584 (2010) 4019–4026In conclusion, our present study supports a novel pro-apoptotic
role for SP600125 in conjunction with DHA. This is the ﬁrst report
that SP600125 synergistically enhances the DHA-induced ASTC-a-
1 cell apoptosis by accelerating Bax translocation and subsequent
mitochondrial apoptotic pathway.Acknowledgements
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